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ORIGINAL ARTICLE
Synbiotic approach restores intestinal homeostasis
and prolongs survival in leukaemic mice with
cachexia
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Cancer cachexia is a multifactorial syndrome that includes muscle wasting and inflammation. As gut
microbes influence host immunity and metabolism, we investigated the role of the gut microbiota in
the therapeutic management of cancer and associated cachexia. A community-wide analysis of the
caecal microbiome in two mouse models of cancer cachexia (acute leukaemia or subcutaneous
transplantation of colon cancer cells) identified common microbial signatures, including decreased
Lactobacillus spp. and increased Enterobacteriaceae and Parabacteroides goldsteinii/ASF 519.
Building on this information, we administered a synbiotic containing inulin-type fructans and live
Lactobacillus reuteri 100-23 to leukaemic mice. This treatment restored the Lactobacillus population
and reduced the Enterobacteriaceae levels. It also reduced hepatic cancer cell proliferation, muscle
wasting and morbidity, and prolonged survival. Administration of the synbiotic was associated with
restoration of the expression of antimicrobial proteins controlling intestinal barrier function and gut
immunity markers, but did not impact the portal metabolomics imprinting of energy demand. In
summary, this study provided evidence that the development of cancer outside the gut can impact
intestinal homeostasis and the gut microbial ecosystem and that a synbiotic intervention, by
targeting some alterations of the gut microbiota, confers benefits to the host, prolonging survival and
reducing cancer proliferation and cachexia.
The ISME Journal advance online publication, 27 November 2015; doi:10.1038/ismej.2015.209
Introduction
The trillions of microbes that reside in the gastro-
intestinal tract of mammals (that is, the gut micro-
biota) maintain a symbiotic relationship with their
host. The gut microbiota has a critical role in
biological processes such as maturation of the
immune system and host metabolism (Hooper
et al., 2012; Brestoff and Artis, 2013). Reciprocally,
the host’s immune system affords protection against
microbes and partially determines the composition
of the gut microbiota. This is achieved in part
through the creation of a barrier that involves several
factors, including secretion of glycoproteins
(mucins), expression of tight junction proteins,
release of agents that prevent the translocation of
gut microbes (for example, immunoglobulin A)
and secretion of antimicrobial proteins such as
regenerating islet-derived 3 gamma (Reg3γ), secre-
tory group IIA phospholipase A2 (Pla2g2) and
α-defensins (Bevins and Salzman, 2011; Hooper
et al., 2012; Mukherjee and Hooper, 2015). The
appreciation that the gut microbiota has an essential
role in human and animal health has generated
tremendous interest in strategies to modulate its
composition and metabolic function to benefit the
host. Prebiotics are one of these strategies. Prebiotics
typically refer to non-digestible compounds that, by
being substrates for microorganisms in the gut,
modulate the composition and/or activity of the gut
microbiota, thus conferring a beneficial physiological
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effect to the host (Gibson and Roberfroid, 1995;
Gibson et al., 2004; Bindels et al., 2015). The
modulation of the gut microbiome has shown
benefits in several experimental disease models, for
example, inflammatory bowel diseases, obesity, type
2 diabetes, hepatic steatosis, gastrointestinal cancers,
and allergic airway disease (Schwabe and Jobin,
2013; Tilg and Moschen, 2014; Bindels et al., 2015).
The potential role of gut microbes in carcinogen-
esis and cancer progression in the gastrointestinal
tract has been an object of research for decades
(Schwabe and Jobin, 2013; Louis et al., 2014).
Recently, it has been demonstrated that the micro-
biome could also impact the occurrence and progres-
sion of cancer at extra-intestinal sites (Schwabe and
Jobin, 2013). Reciprocally, it has been shown in
rodent models that the gut microbiota is altered by
cancers that occur outside the gastrointestinal tract
(Lin et al., 2012; Bindels et al., 2012a,b). Because the
gut microbiota participates in the regulation of host
immunity and metabolism, it is of crucial importance
from a therapeutic perspective to determine whether
it has a role in tumour progression and associated
metabolic disorders (often referred to as cancer
cachexia) and to further elucidate the mechanisms
underlying such interactions.
Cachexia is a serious but often neglected conse-
quence of many chronic diseases. Its prevalence
ranges from 5% to 15% of patients in end-stage
chronic heart failure up to 50–80% of patients with
advanced cancer (Argiles et al., 2014; von Haehling
and Anker, 2014). Cancer cachexia is characterized by
a loss of fat and muscle masses that is often
accompanied by anorexia and inflammation (Argiles
et al., 2014). Cancer cachexia remains an unmet
medical need, and its treatment will likely require a
multimodal therapeutic approach that combines
nutritional support with exercises and pharmacologi-
cal agents targeting the breakdown of skeletal muscle
and inflammation (Fearon et al., 2012, 2013). We have
previously shown that the administration of specific
Lactobacillus strains or non-digestible carbohydrates
fermented by gut microbes can reduce systemic
inflammation and/or cancer progression (Bindels
et al., 2012a,b), suggesting that the gut microbiome
might be a potential therapeutic target for cancer
cachexia. These studies raised several questions: how
is the composition of the gut microbiota affected in
cancer cachexia? Do the gut microbiota and the
intestine have a role in cancer cachexia? What are
the mechanisms involved in this crosstalk?
In this study, we used next-generation sequencing,
metabolomics and molecular profiling of the host to
gain in-depth insight regarding the impact of cancer
and cachexia on the composition of the gut micro-
biota and to identify pathways that are potentially
involved in these gut microbiota–host interactions.
Using these approaches, we identified bacterial taxa
that were associated with alterations of the intestinal
homeostasis. The information obtained in the first
studies was used to design a dietary approach
combining the oral administration of a bacterium
that is known to be decreased in cancer cachexia
(Lactobacillus reuteri) and a prebiotic (inulin-type
fructans, ITF). We then determined the effect of this
synbiotic treatment on lifespan and other physiolo-
gical hallmarks of cancer cachexia.
Materials and methods
Cell culture
Colon carcinoma 26 (C26) cells were maintained in
DMEM high-glucose medium supplemented with
10% fetal bovine serum (PAA clone, PAA, Pasching,
Austria), 100 μgml−1 streptomycin and 100 IUml− 1
penicillin (Gibco, Ghent, Belgium) at 37 °C with 5%
CO2. The Pro-B lymphocyte (BaF3/BaF) cell line
transfected with Bcr-Abl was maintained as pre-
viously described (Bindels et al., 2012a).
Bacterial culture and in vitro testing
L. reuteri was grown at 37 °C in MRS medium (Difco,
Franklin Lakes, NJ, USA) until the stationary phase
and then washed. For peripheral blood mononuclear
cell (PBMC) stimulation, the bacteria were suspended
in phosphate-buffered saline containing 20% gly-
cerol and stored at −80 °C until use. For the in vivo
experiments, bacterial culture was centrifuged,
supernatant removed and pelleted bacteria stored at
−80 °C. Bacterial numerations were checked after
thawing, and the bacteria were suspended at an
adequate concentration. PBMCs were isolated from
the blood of healthy donors as described previously
(Foligne et al., 2007). Briefly, after Ficoll gradient
centrifugation (Pharmacia, Stockholm, Sweden),
mononuclear cells were collected, washed in
RPMI-1640 medium (Life Technologies, Ghent,
Belgium), and adjusted to 2×106 cells per ml in
RPMI supplemented with gentamicin (150 gml−1), L-
glutamine (2mM), and 10% fetal calf serum (Gibco).
PBMCs were stimulated with phosphate-buffered
saline or bacteria (bacterium:cell ratio of 10:1) for
24 h at 37 °C with 5% CO2. The supernatants were
collected and stored at −20 °C until cytokine mea-
surements were performed using R&D Duoset ELISA
kits (R&D, Minneapolis, MN, USA).
Animals
Mice from Charles River Laboratories (Chatillon-
sur-Chalaronne, France) were housed at two mice
per cage with a 12-h light/dark cycle and fed an
irradiated normal chow diet (AO4-10, 2.9 kcal g− 1,
Safe, Augy, France). Six to ten mice were included in
each group, as indicated in the legends.
C26 model. Either a saline solution or C26 cells
(1 × 106 cells in 0.1ml saline) were injected sub-
cutaneously (intrascapular) in male CD2F1 mice
(8 weeks old).
BaF model. Either a saline solution or BaF cells
(1 × 106 cells in 0.1ml saline) were injected into
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the tail vein of anesthetized female Balb/c mice
(6 weeks old). The dietary restriction experiment is
described in the Supplementary information. For the
synbiotic treatment, 1 day after the BaF injection,
the mice received Lactobacillus reuteri 100-23
(2 × 108 CFU per ml) with 0.2 g per day of ITF
(oligofructose, Orafti p95, 1.5 kcal g− 1, Beneo-Orafti,
Oreye, Belgium) in the drinking water, as previously
described (Bindels et al., 2012a, b). The drinking
solutions were replaced every day, and food and
water intake were recorded. Synbiotic mice con-
sumed on average 5.8 × 108 CFU per day for the main
experiment and 6.34× 108 CFU per day for the
survival experiment (Supplementary Figure S1).
Energy intake was calculated taking into account
the energy content of the diet and energy from ITF.
At the end of the experiment (11 days for the C26
model and 13 days for the BaF model), portal blood
and tissue samples were harvested following anaes-
thesia (ketamine and xylazine, or isoflurane gas,
Abbot, Wavre, Belgium). Portal blood was collected
in EDTA tubes and centrifuged (13 000 g, 3 min).
Tissues were weighed and frozen in liquid nitrogen.
All of the samples were stored at − 80 °C.
For the survival experiment, a separate set of mice
was used. Half the mice received the synbiotic
treatment, as described above. A morbidity score
was performed on day 14 as described in the
Supplementary information. Mice were monitored
every 3–6 h from day 15 to day 19. All mice died
from cancer, and therefore, no tissues and blood
were withdrawn.
The experiments were approved by the ethics
committee of the Université catholique de Louvain,
and the housing conditions were consistent with the
specifications of the Belgian Law of 29 May 3013 for
the protection of laboratory animals (Agreement LA
1230314).
Tissue mRNA analyses
The isolation of RNA, preparation of complementary
cDNA and real-time PCR were performed as pre-
viously described (Bindels et al., 2012a). The RNA
quality was checked using an Agilent 2100 Bioana-
lyzer (Agilent Technologies, Santa Clara, CA, USA).
The primer sequences are detailed in Supplementary
Table S1. Full description of the quantitative real-
time PCR (qPCR) procedures is provided in the
Supplementary information.
Gut microbiota analyses
Genomic DNA was extracted from the caecal content
using a QIAamp DNA Stool Mini Kit (Qiagen,
Hilden, Germany), including a bead-beating step.
Absolute quantification of the bacterial taxa was
performed by qPCR (primers presented in
Supplementary Table S1). Full description of the
qPCR procedures is provided in the Supplementary
information. Illumina sequencing was performed as
previously described (Krumbeck et al., 2015). The
V5-V6 region of the 16S rRNA gene was amplified by
PCR with modified primers. The amplicons were
purified, quantified and sequenced using an Illu-
mina Miseq to produce 2x300-bp sequencing pro-
ducts at the University of Minnesota Genomics
Center. Initial quality-filtering of the reads was
conducted with the Illumina Software, yielding an
average of 148 370 pass-filter reads per sample.
Quality scores were visualized and reads were
trimmed to 240 bp. The reads were merged with
the merge-Illumina-pairs application (Eren et al.,
2013). For samples with 450 000 merged reads, a
subset of 50 000 reads was randomly selected using
Mothur 1.32.1 (Schloss et al., 2009) to avoid large
disparities in the number of sequences. Subse-
quently, the UPARSE pipeline implemented in
USEARCH v7.0.1001 (Edgar, 2013) was used to
further process the sequences. Putative chimaeras
were identified against the Gold reference database
and removed. Clustering was performed with a 98%
similarity cutoff to designate operational taxonomic
units (OTUs). Non-chimaeric sequences were also
subjected to taxonomic classification using the RDP
MultiClassifier 1.1 from the Ribosomal Database
Project (Cole et al., 2014) for phylum to genus
characterization of the faecal microbiome.
The phylotypes were computed as percent
proportions based on the total number of sequences
in each sample. Alpha- and beta-diversity indexes
were calculated using QIIME (Caporaso et al., 2010).
The LDA effect size was computed and plotted
using LEfSe (Segata et al., 2011). The complete
protocol, statistical analysis and accession numbers
are provided in the Supplementary materials and
methods.
Metabolic profiling by 1H NMR spectroscopy
In all, 50 μl of portal plasma was mixed with 10 μl of
D2O, vortexed and centrifuged, and the supernatant
was transferred into NMR capillary tubes. The
complete protocol and statistical analysis are
described in the Supplementary materials and
methods.
Statistical analyses
The statistical significance of differences between
groups was assessed using Student’s t-test when
comparing two groups, or one-way ANOVA followed
by Tukey’s multiple comparison post hoc test when
comparing several groups. The data are presented as
the mean± s.e.m. or as whiskers plots with minima
and maxima. Po0.05 was considered as statistically
significant. More information is provided in the
Supplementary materials and methods.
Results
Cancer development alters the caecal microbiota
Two models of cancer cachexia were used: the BaF
model and the C26 model. The BaF model involves
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the intravenous injection of Bcr-Abl-expressing
lymphocytes, thereby mimicking acute leukaemia
(Bindels et al., 2012b). The C26 model consists of a
subcutaneous injection of colon 26 (C26) tumour
cells (Sciorati et al., 2009; Talbert et al., 2014). Both
models are characterized by a loss of fat mass and
muscle atrophy, as published previously for the BaF
model (Bindels et al., 2012a) and as shown in
Supplementary Figure S2 for the C26 model. The
caecal microbiota analysis by Illumina sequencing of
16S rRNA tags revealed profound shifts in the
composition of the microbiota in both models, as
evidenced by principal coordinates analysis of the
Morisita-Horn beta-diversity at the OTU level
(Figures 1a and b). The three first principal coordi-
nates explained 74% and 95% of the variation for the
BaF and C26 models, respectively. Alpha-diversity
indexes of richness (observed species), or richness
and evenness (Shannon), were decreased in BaF and
C26 mice compared with their healthy counterparts
(Figures 1c and d). In the BaF and C26 models, 25
and 54 taxa were affected, respectively. The changes
common to both models encompassed a decrease in
the Clostridiales order, Clostridia class, Lactobacil-
laceae family and Lactobacillus genus, and an
increase in the Enterobacteriaceae family, Entero-
bacteriales order, Parabacteroides genus and Bacter-
oidetes phylum (Figures 1e and f). In the C26 model,
using an OTU-based analysis, we identified 70
significantly affected phylotypes. Among others,
OTU 17 and OTU 97 (both identified as Escherichia)
were increased by 2698-fold and 4676-fold, respec-
tively, while the relative abundance of OTU 2
(identified as Parabacteroides goldsteinii/ASF 519)
increased from 1% to 30% of the total 16S rDNA
sequences. OTU 54 (identified as Lactobacillus
johnsonii/gasseri) showed a four-fold decrease
(Supplementary Table S2). qPCR analysis of Enter-
obacteriaceae, P. goldsteinii/ASF 519 and Lactoba-
cillus spp. shows trends similar to the
pyrosequencing results (Supplementary Figure S3).
Cachectic mice exhibited reduced food intake
(Supplementary Figure S4). To explore whether the
modification of the specific taxa was due to changes in
food intake, healthy mice were dietary restricted to
mimic the decreased food intake of the BaF mice, and
the same taxa were analysed by qPCR (Supplementary
Figure S4). This experiment allowed us to conclude
that the changes in Lactobacillus and Enterobacter-
iaceae that occur in cancer and the associated
cachexia were not due to decreased food intake.
This set of experiment led us to the conclusion
that, in two mouse models of cancer and cachexia,
the gut microbiota is impacted by the development
of cancer outside the gastrointestinal tract.
A synbiotic approach reduces the progression of cancer
and associated cachexia
To further investigate the therapeutic potential of the
gut microbiota, we applied a synbiotic approach by
combining ITF, a well-known prebiotic, and a
Lactobacillus species. The rationale for the use of
dietary lactobacilli was that these bacteria were
consistently reduced during cachexia, especially in
the BaF model. In addition, we demonstrated in a
previous study that the administration of a mixture
of L. gasseri 311476 and L. reuteri 100-23 reduced
systemic inflammation and muscle atrophy in the
BaF model (Bindels et al., 2012a). In vitro
co-incubation of each bacterial strain with human
PBMCs suggested that L. gasseri evoked pro-Th1
responses, whereas L. reuteri appeared to possess
more anti-inflammatory properties (Figure 2). There-
fore, L. reuteri 100-23 was selected for the synbiotic
approach and combined with ITF.
BaF mice were fed ITF and L. reuteri (LrI)
throughout the course of the study. Thirteen days
after injection, the LrI-treated mice exhibited
decreased hepatic accumulation of BaF cells, as
evidenced by a reduced liver weight and a lower
expression of Bcr-Abl, a chimaeric protein that is
specifically expressed in BaF cells (Figures 3a and
b). Of note, we previously showed that these two
parameters are key markers of BaF cell accumulation
in the liver (Bindels et al., 2012b). Bcr-Abl expres-
sion in the spleen was not impacted by the synbiotic
treatment (not detected in control mice, BaF:
1.00 ± 0.14; BaF-LrI: 0.90 ±0.11, P-value = 0.59,
n=8). In addition, LrI resulted in the improvement
of some cachectic features such as muscle mass loss
and the expression of atrophy markers in tibialis and
gastrocnemius muscles (Figures 3c and e). In this
experiment, synbiotic treatment did not significantly
impact the daily energy intake (Figure 3f).
A separate set of mice was used to investigate
whether synbiotic treatment can affect morbidity and
mortality. LrI administration lowered the morbidity
score by half and prolonged the survival of mice by
2 days (Figures 3g and h). In this experiment, no
change in energy intake was observed following the
administration of LrI, except on days 1 and 12
(Supplementary Figure S5).
The synbiotic approach changes the gut microbiota
composition
Synbiotic administration led to higher weights of
caecal content and tissue (Supplementary Figure S5).
Illumina sequencing confirmed profound shifts in
the structure of the microbiota associated with
cancer development, and it revealed that the synbio-
tic approach counteracted some of those changes
(Figures 4 and 5, Supplementary Figure S5,
Supplementary Tables S3 and S4). At the genus
level, BaF injection was associated with the enrich-
ment of Parabacteroides, Clostridium XI, Anaero-
truncus and Escherichia, and the reduction of
Barnesiella, Lactobacillus, Blautia, Clostridium XIVb
and Parasutterella, among others; several of these
changes were observed in previous experiments
(Figures 4 and 5, Supplementary Figure S6 and
Supplementary Table S3). LrI reversed the increased
Synbiotics prolong survival in leukaemic mice
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Figure 1 Shifts in the composition of the gut microbiota in the BaF and C26 models. (a, b) Principal coordinate analysis of the Morisita-Horn
beta-diversity index computed based on the OTU table. (c, d) Alpha-diversity indexes in cancer-bearing mice vs controls (CT). The observed
species represent an index of richness, and the Shannon index takes into account the richness and evenness. (e, f) LDA scores in red for the taxa
enriched in cancer-bearing mice and in green for the taxa enriched in control mice. N=6–8, *Po0.05, **Po0.01, ***Po0.001.
Synbiotics prolong survival in leukaemic mice
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abundances of Escherichia and Anaerotruncus,
whereas it increased the relative abundances of the
Coriobacteriaceae family, Clostridium cluster XVIII,
and some genera such as Barnesiella, Lactobacillus,
Bifidobacterium and Parasutterella (Figures 4 and 5,
Supplementary Figure S6). The OTU-based analyses
confirmed these results and indicated a five-fold
increase in the relative abundance of the segmented
filamentous bacteria (SFB, OTU 185) (Figure 5,
Supplementary Figure S7 and Supplementary
Table S4). Quantification of Enterobacteriaceae,
P. goldsteinii/ASF 519 and Lactobacillus spp. by qPCR
confirmed the pyrosequencing results (Figures 5d–g).
Of note, five of the eight bacterial taxa previously
found to be commonly affected in both BaF and C26
models were similarly influenced by cancer devel-
opment in this new set of experiments (namely,
the Lactobacillaceae family, Lactobacillus genus,
Enterobacteriaceae family, Enterobacteriales order
Figure 2 L. gasseri evokes pro-Th1 responses, whereas L. reuteri
appears to possess more anti-inflammatory properties. Cytokine
levels in the medium after co-culture of human PBMC and
Lactobacillus species (two independent experiments involving a
total of nine PBMC donors). *Po0.01 vs medium, #Po0.01 vs
L. gasseri 311476.
Figure 3 The synbiotic approach reduces hepatic cancer cell accumulation and cachectic features in leukaemic mice. (a) Liver weight.
(b) Bcr-Abl mRNA expression in the liver. ND, not detected. (c) Muscle weights. (d, e) mRNA expression of atrophy markers in the tibialis
and gastrocnemius muscle. (f) Daily energy intake. (g) Morbidity score performed at day 14. (h) Kaplan–Meier curve showing the survival
fractions analysed by the log-rank test (P=0.007). N=8 for (a–f) and n=10 for (g) and (h), *Po0.05 vs control, #Po0.05 vs BaF, ##Po0.01
vs BaF, $P=0.06 vs BaF.
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Figure 4 The synbiotic approach changes the gut microbiota composition. (a) LEfSe cladogram in red for the taxa enriched in BaF mice
and in green for the taxa enriched in control mice. (b) LEfSe cladogram in red for the taxa enriched in BaF mice and in green for the taxa
enriched in BaF-LrI mice. N=8.
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and Parabacteroides genus) (Figure 4 and
Supplementary Figure S6). This microbial signature
(increase in the levels of Enterobacteriaceae and
P. goldsteinii/ASF 519 and decrease in Lactobacillus
levels) was also observed in two additional BaF
experiments performed 18 months apart, demon-
strating the reproducibility of our findings
(Supplementary Figure S8).
Cancer progression changes the portal metabolome
To better understand how changing the composition
and activity of the gut microbiota could reduce cancer
cell proliferation and the underlying cachexia, we
performed a metabolomics analysis of the portal blood
of mice. Principal coordinate analysis of the metabolic
profiles revealed clear clustering of the control mice
due to the enrichment of glucose, fumarate and
lipoproteins in the control group and of lactate,
creatine and succinate in the BaF and BaF-LrI groups
(Figure 6). A pairwise comparison of the NMR profiles
of BaF and BaF-LrI mice did not highlight discriminant
metabolites. O-PLS regressions on significantly
affected OTUs and PCR transcripts revealed that
plasma lipoproteins were negatively associated with
the presence of some microorganisms, such as an
unclassified Porphyromonadacae (OTU 88) and the
Enterobacteriaceae family (Supplementary Figure S9).
Synbiotic-mediated improvements in intestinal
immune and barrier biomarkers correlate with
microbial changes
To identify putative mechanistic links between
microbial dysbiosis and cancer and cachexia, we
characterized the gut microbiota–host crosstalk at
the intestinal level. Antimicrobial peptides greatly
affect the composition of the gut microbiota
Figure 5 The synbiotic approach changes the abundance of several bacterial taxa. (a) Species enriched in BaF mice according to the
LEfSe analysis. (b) Clostridium cluster XVIII. (c) SFB/OTU 185. (d–g) Bacteria levels in the caecal content of BaF mice fed or not the
synbiotic, as determined by qPCR. AU, arbitrary units. N=8, *Po0.05 vs control, #Po0.05 vs BaF.
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Figure 6 Cancer progression changes the portal metabolome. (a) Principal coordinate analysis plot of the metabolomics profiles derived
from portal plasma of control (blue), BaF (red) and BaF-LrI (green) mice, and associated loadings of PC2 (b) and PC1 (c). Pairwise O-PLS-
DA comparison showing the calculated scores (x axis) against the cross-validated scores (y axis) and their associated loading coefficients.
The weights of the variables are color-coded according to the square of the O-PLS-DA correlation coefficients. (d, e) Controls vs BaF and
(f, g) controls vs BaF-LrI. N=6–8.
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(Bevins and Salzman, 2011). Here, the expression of
antimicrobial proteins such as Lysozyme 1, Reg3γ
and Pla2g2 was decreased in BaF mice, as well as the
expression of TCF4 (T cell-specific transcription
factor 4), which drives Paneth cell differentiation
(Figure 7a) (Bevins and Salzman, 2011). Whereas
antimicrobials constitute a chemical barrier against
pathogens and commensals, tight junction proteins,
such as zonula occludens 1 (ZO-1) and occludin, and
mucus secretion participate to construct a physical
barrier that limits host exposure to gut microbes. BaF
cell injection decreased the expression of occludin,
zonula occludens 1 and Muc2 (Figure 7b). The
expression levels of immune markers of inflamma-
tion (TNF-α, IFN-γ and IL-1β), the innate immune
system (CD11b), proinflammatory macrophages
(CD11c), T lymphocytes (CD3γ), Th1 lymphocytes
(Tbet) and Th17 lymphocytes (IL-17A) were also
decreased in the presence of cancer, whereas IL-6
and the macrophage pan-markers F4/80 and CD68
remained unaffected (Figures 7c and d). Interest-
ingly, the administration of LrI counteracted most of
the BaF-induced alterations detected in the intestine.
Although ITF have been shown to improve gut
barrier function through an increase in the produc-
tion of glucagon-like peptide 2 (Cani et al., 2009), LrI
administration did not increase the mRNA expres-
sion of proglucagon, the precursor of glucagon-like
peptide 2 in this study (Figure 7b).
Regulatory T (Treg) cells, a subset of lymphocytes
that restrain the immune response, contribute to
intestinal and systemic immune homeostasis and
Figure 7 The synbiotic approach improves intestinal immune and barrier biomarkers in leukaemic mice. (a) mRNA expression of
markers involved in Paneth cell differentiation and antimicrobial proteins. (b) mRNA expression of markers involved in gut permeability.
(c) mRNA expression of immune markers related to inflammation, innate immunity (CD11b) and macrophages. (d) mRNA expression of
immune markers related to lymphocytes (CD3γ) Th1 (Tbet), Th17 (IL-17A) and Treg (Foxp3, IL-10, Ebi3) cells. N=7–8, *Po0.05 vs
control, #Po0.05 vs BaF.
Synbiotics prolong survival in leukaemic mice
LB Bindels et al
10
The ISME Journal
can be induced by commensal microbiota (Rubtsov
et al., 2008; Arpaia et al., 2013; Atarashi et al., 2013).
Treg development is controlled by the transcription
factor Foxp3, while the function of Tregs is mediated
by IL-35 and IL-10 (Collison et al., 2007; Gavin et al.,
2007). Intestinal Foxp3 and IL-10 expression was
reduced in BaF mice and restored following LrI
treatment, whereas the expression of Ebi3, a subunit
of the heterodimeric cytokine IL-35, was not
impacted by cancer but was induced in response to
LrI (Figure 7d). The immunomodulatory effect of LrI
was not limited to the gastrointestinal tract. Indeed,
LrI administration increased Foxp3 mRNA levels
in the spleen (BaF: 1.0 ± 0.1; BaF-LrI: 2.0 ± 0.4,
P=0.047), and this increase correlated with the
relative abundance of Clostridium Cluster XVIII
(Pearson r=0.71, P=0.002), a group of microbes that
is able to induce Tregs (Atarashi et al., 2013).
Finally, a multiple correlation analysis between
intestinal biomarkers and phylotypes that were
significantly affected highlighted Escherichia sp.
and P. goldsteinii/ASF 519 as two bacteria that
correlated inversely with intestinal alterations.
In addition, several OTUs, encompassing mainly
Barnesiella, Lactobacillus, Enterorhabdus and
unclassified Porphyromonadaceae species, corre-
lated with Reg3γ, CD11b, CD11c and CD3γ expres-
sion (Figure 8, Supplementary Table S5).
Discussion
In this study, we demonstrated that the gut microbial
balance was altered by the presence of tumours
located outside the gastrointestinal tract, consis-
tently with our previous study where we provided
the first evidence of a modified gut microbiome in a
mouse model of leukaemia and cachexia (BaF)
(Bindels et al., 2012a). Caecal Lactobacillus spp.
levels were decreased in leukaemic mice with
cachexia, and a PCR-DGGE (denaturing gradient gel
electrophoresis) analysis suggested that bacteria
other than lactobacilli were affected by the disease.
The same year, Lin et al. (2012) reported that
subcutaneous implantation of colon cancer cells in
rats was associated with a one-log increase in
Enterobacteriaceae and Clostridium cluster I and XI
in the faeces. In both studies, microbial dysbiosis
was assessed using molecular approaches with
limitation in dynamic range. Here we used a
community-wide molecular approach to deeply
characterize the microbial shifts occurring in two
mouse models of cancer cachexia. Our data revealed
a microbial signature common to both models that
included the Enterobacteriaceae family/Escherichia
genus, Lactobacillus genus and Parabacteroides
goldsteinii/ASF 519 species. Some of these changes
have also been observed in the previous studies
(Lin et al., 2012; Bindels et al., 2012a), and have been
reported as a sign of reduced colonization resistance
(Lawley and Walker, 2013).
One potential mechanism for the dysbiosis
observed during cachexia in mice might be the
associated reduction in food intake observed at the
late stage of the disease. Food intake has been
reported to influence the composition of the gut
microbiota (Crawford et al., 2009), and it may be
considered that this reduced food intake constitutes
a confounding factor in this mouse model. However,
one must consider that anorexia is a fully fledged
hallmark of cachexia, and thus, it should be
integrated into experimental models. Our experi-
ments revealed that the major shifts (Enterobacter-
iaceae and lactobacilli) occurred independently
of food intake, suggesting that the presence of
cancer cells impacts the gut microbial ecology
Figure 8 Synbiotic-mediated improvements in intestinal
immune and barrier biomarkers correlate with microbial changes.
Heat map representation of the Pearson’s r correlation coefficient
between intestinal biomarkers and significantly affected phylo-
types. The closest known taxon is indicated with the OTU number
within brackets. *Adjusted Po0.05.
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independently of food intake. Nonetheless, even if
anorexia contributes to dysbiosis, it would not
impair the therapeutic implication of our findings.
Synbiotic treatment modified to a very limited extent
daily energy intake of cachectic mice in one out of
two experiments. We can consider that the impact is
minor compared with the leukaemia-induced
reduced energy intake and likely not relevant
enough to be taken into consideration for the
interpretation of the data.
Our study results clearly demonstrated gut
microbiota alterations in two different models of
cachexia. These findings raise the question of
whether this dysbiosis contributes to the observed
pathologies. We have previously demonstrated
the therapeutic interest of the restoration of lactoba-
cilli (Bindels et al., 2012a). To our knowledge,
the role of microorganisms, such as Escherichia
and P. goldsteinii/ASF 519, in cancer cachexia has
not been investigated yet. P. goldsteinii/ASF 519 is a
mouse commensal species that is also found at low
levels in humans (Dewhirst et al., 1999; Song et al.,
2005). The ELDERMET study (Claesson et al., 2012)
indicated that individuals in long-term care
developed dominant levels of Parabacteroides and
Alistipes that were associated with changes in frailty,
inflammation and altered abundances of short-chain
fatty acid producers. Similarly to P. goldsteinii, the
genus Escherichia encompasses rodent and human
commensal strains and is present at low levels in
healthy subjects. Some strains are beneficial to the
host, whereas others have been associated with
inflammatory bowel disease and colorectal cancer
(Manichanh et al., 2012; Louis et al., 2014; Sha et al.,
2014). In our study, the synbiotic approach reduced
the levels of Enterobacteriaceae. This phenomenon
could be mediated by short-chain fatty acids (acetate,
propionate and butyrate), the production of which is
fostered by ITF (Bindels et al., 2012b; Everard et al.,
2014), and which, in association with a decreased
caecal pH, create a non-permissive environment for
colitogenic Enterobacteriaceae (Veiga et al., 2010).
Additional research is needed to establish whether
the gut microbiota has a role in cancer cachexia. Yet,
based on our findings, the following hypothesis
can be formulated. Systemic inflammation due to
cancer development will alter the gut permeability,
antimicrobial defence and Paneth cell function,
leading to dysbiosis. Thereafter, the altered intestinal
homeostasis, microbial dysbiosis and cancer
cachexia would interact in a vicious cycle, where
cancer-induced alterations of intestinal homeostasis
foster the growth of certain bacteria that further
increase systemic inflammation and cachexia. This
hypothesis is supported by several elements, inde-
pendently of the data presented herein. First,
systemic inflammation, which has a key role in
cancer cachexia (Fearon et al., 2012, 2013; Argiles
et al., 2014; von Haehling and Anker, 2014), is
present in BaF and C26 mice (Fearon et al., 2012;
Bindels et al., 2012a, b) and increases epithelial
permeability (Ivanov et al., 2010). Moreover, inflam-
mation boosts the growth of Enterobacteriaceae and
E. coli and creates an opportunity for E. coli to
adhere to the colonic mucosa by decreasing the
production of mucins and antimicrobials (Lupp
et al., 2007; Winter et al., 2013; Louis et al., 2014).
Finally, a similar relationship among Paneth cells,
the loss of bacterial diversity, E. coli blooming and
immune alterations has recently been reported in
other mouse models (Inaba et al., 2010; Arthur et al.,
2012; Eriguchi et al., 2012).
In addition to establishing the presence of micro-
bial shifts in cancer cachexia, the results of the
present study clearly provided evidence for con-
sidering the gut microbiota as a therapeutic target in
cancer and cachexia. Indeed, nutritional modulation
of the microbiome by combined pre and probiotic
approaches resulted in the reduction of cancer cell
proliferation and an improvement of the cachectic
features, thus leading to prolonged survival. As
L. reuteri is not able to metabolize ITF, this
combination would be called a complementary
synbiotic approach (Kolida and Gibson, 2011).
Our data obtained in vitro confirmed that L. reuteri
100-23 is rather anti-inflammatory. Therefore, one
could speculate that such immune modulation could
foster cancer proliferation (Mantovani et al., 2008).
However, this was not observed here.
To unravel the mechanisms by which the synbio-
tic approach provides its benefits, we performed 16S
sequencing of the gut microbiota, metabolomic
analysis of the portal blood and molecular character-
ization at the intestinal level, which allowed us to
draw some hypotheses regarding the mechanism(s)
underlying the benefits of the synbiotic treatment.
First, the synbiotic approach could mediate its
benefits through the restoration of intestinal home-
ostasis. The implication of elevated gut permeability
in cancer cachexia has been recently proposed
(Puppa et al., 2011; Bindels and Delzenne, 2013).
Our data clearly showed that cancer cells implanted
at a distance from the gastrointestinal tract can
affect the gut barrier and immune function. The
changes in gut barrier function may contribute to
the inflammatory status and thereby to the cachectic
phenotype. By restoring the gut barrier function, the
synbiotic treatment may impact systemic inflamma-
tion, as described in other pathological contexts
(Cani et al., 2009).
Second, the synbiotic approach could modulate
immunity by increasing the abundance of bacterial
taxa with immunomodulatory properties, such as
Clostridium cluster XVIII, the SFB and Lactobacillus
reuteri 100-23. Atarashi et al. (2013) have previously
demonstrated that a selected mixture of Clostridia
strains falling within Clostridium clusters IV, XIVa
and XVIII was able to induce Tregs. In accordance
with this result, we found a strong correlation
between Clostridium cluster XVIII and the expres-
sion of Foxp3 in the intestine and in the spleen. The
SFB have a unique ability to educate the gut immune
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system and to induce a healthy state of physiological
inflammation, notably through the IL-17 pathway
(Ivanov et al., 2009; Schnupf et al., 2015). Accord-
ingly, intestinal IL-17A expression increased in
response to the synbiotic treatment. Finally, because
L. reuteri 100-23 caused a slight increase in the
numbers of Tregs in the spleen of Lactobacillus-free
mice (Livingston et al., 2010), the synbiotic-induced
increase in Foxp3 expression may also be directly
mediated by L. reuteri 100-23.
The portal metabolome reflected mainly a state of
energy demand in leukaemic mice, where signifi-
cantly decreased glucose and lipoproteins levels,
concomitant with increased levels of creatine and
lactate, were observed. Increased creatine levels are
typical of muscle wasting and consistent with the
cachectic model. The increased lactate level in the
portal plasma of leukaemic mice was likely a
consequence of lactate production by BaF cells as
previously reported (Bindels et al., 2012b). Succi-
nate, an intermediate product in the Krebs cycle of
endogenous and microbial origin, was also enriched
in leukaemic mice. The metabolomic analysis did
not highlight any portal metabolite discriminant for
the synbiotic intervention. The lack of discriminant
metabolites reinforces the hypothesis that the syn-
biotic approach provides a benefit via subtle changes
in immunity or by impacting metabolic pathways
that produce metabolites in low levels, such as
propionate, which although detected, was below the
limit of quantification in this study. Indeed, we have
previously provided strong evidence to suggest that
propionate produced through the bacterial fermenta-
tion of ITF reduces the proliferation of BaF cells in
the liver (Bindels et al., 2012b).
The present study demonstrated that cancer
cachexia was associated with profound alterations
of the gut microbiota in two animal models. Our data
further showed that dietary modulation of the gut
microbiota that mitigated some of the dysbiotic
patterns restored the intestinal gut barrier and
immune function, thereby reducing cancer and
associated cachexia. In addition, the synbiotic
approach prolonged survival, a relevant primary
outcome for nutrition therapy in cancer (Baracos
et al., 2012). As all of the animal models have their
limitations, exploration of the gut microbial ecosys-
tem in cancer patients with cachexia is now needed
before any extrapolation to humans. Which doses of
synbiotics would have to be used in clinical trials to
translate our findings remains highly speculative.
Useful information can be obtained from published
works, mainly in the context of metabolic alterations
linked to obesity, which pointed out changes in the
gut microbiota similar in mice and obese women
upon prebiotic consumption that were associated
with improvement of host metabolism (Dewulf et al.,
2013).
Together, these data suggest a role for the gut
microbiota and the intestinal barrier in the thera-
peutic management of cancer and associated
cachexia. Future studies will be focused on investi-
gating the causative role of specific gut microbes and
altered intestinal homeostasis in the progression of
cancer and associated cachexia, and assess the
relevance of our findings in cancer patients with
cachexia.
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